Joslin Diabetes Center

Joslin Diabetes Center

Diabetes research, care, and education center

Overview

Joslin Diabetes Center focuses on diabetes care, research, and education. It runs adult and pediatric clinics, eye care, nutrition and exercise programs, and a patient portal that helps people manage appointments, billing, and health information. The center combines medical treatment with ongoing research and education to support patients, families, and healthcare professionals. It differentiates itself by being a long-established not-for-profit institution that integrates clinical care with a robust research program, patient education, and community outreach (including multicultural programs) under one umbrella. Its goal is to improve the lives of people with diabetes by advancing science, expanding access to care, and training the next generation of diabetes health professionals.

About Joslin Diabetes Center

Simplify's Rating
Why Joslin Diabetes Center is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Education

Healthcare

Company Size

501-1,000

Company Stage

Debt Financing

Total Funding

$10.8M

Headquarters

Boston, Massachusetts

Founded

1898

Get referred to Joslin Diabetes Center

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 brown-fat findings opened a drug-development path for obesity and type 2 diabetes.
  • The Lilly Lulu Foundation backed Joslin's Young Adult T1D Initiative with $250,000 in 2025.
  • HAPPY T1D finished in 2026 with 217 participants, strengthening Joslin's pediatric-to-young-adult pipeline.

What critics are saying

  • One Joslin Place is being demolished for Dana-Farber's hospital, forcing long-term displacement by 2031.
  • Public visibility now depends on Beth Israel Lahey infrastructure, reducing Joslin's standalone control.
  • If Joslin cannot keep clinical volume and grants, its research brand weakens quickly.

What makes Joslin Diabetes Center unique

  • Joslin pairs specialty diabetes care with research; its 2026 Nature Metabolism study proves depth.
  • The Young Adult Program targets T1D distress and glycemia, not just routine endocrinology.
  • Joslin's 20 labs and four cores moved into CLS in 2025, preserving research density.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$10.8M

Above

Industry Average

Funded Over

1 Rounds

Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
KalVista Pharmaceuticals
Jun 2nd, 2026
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer | KalVista Pharmaceuticals

–  Leading Plasma Kallikrein Researcher Further Strengthens Scientific Team – CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom , Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and

Newswise
Mar 11th, 2022
Joslin Diabetes Center, Inc. hires Thomas J. Beatson, Jr as MD, section head

Joslin Diabetes Center is pleased to announce that Chief Scientific Officer George L. King, MD, section head of vascular cell biology, has been named the inaugural incumbent of the Thomas J. Beatson, Jr.

Recently Posted Jobs

Sign up to get curated job recommendations

Joslin Diabetes Center is Hiring for 9 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →